发布求助
文献互助 智能选刊 最新文献

Melanoma Management最新文献

筛选
英文 中文
Advances in the development of intralesional therapies for melanoma. 黑色素瘤内部疗法的研发进展。
IF 1
Melanoma Management Pub Date : 2016-12-01 Epub Date: 2016-11-29 DOI: 10.2217/mmt-2016-0020
Daniel Y Wang, Douglas B Johnson
{"title":"Advances in the development of intralesional therapies for melanoma.","authors":"Daniel Y Wang, Douglas B Johnson","doi":"10.2217/mmt-2016-0020","DOIUrl":"10.2217/mmt-2016-0020","url":null,"abstract":"<p><p>Advances in immune therapy have changed the landscape of advanced melanoma treatment. Intralesional therapy is an important type of immune therapy due to its efficacy and safety, especially in the setting of locoregional metastases. These therapies induce frequent responses in injected lesions as well as distant nontreated lesions through a 'bystander' effect of priming an antitumor immune response. The culmination of nearly a century of innovation has led to the approval of the first US FDA approved intralesional therapy for melanoma in talimogene laherparepvec. Numerous efforts to combine intralesional therapies with systemic immune checkpoint inhibitors are ongoing, whereby a synergistic effect may continue to improve outcomes for patients.</p>","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":"3 4","pages":"259-266"},"PeriodicalIF":1.0,"publicationDate":"2016-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6094591/pdf/mmt-03-259.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10758385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New insights in melanoma biomarkers: long-noncoding RNAs. 黑色素瘤生物标志物的新见解:长链非编码rna。
IF 3.6
Melanoma Management Pub Date : 2016-09-01 Epub Date: 2016-08-16 DOI: 10.2217/mmt-2016-0008
Ricardo Moreno-Traspas, Igor Vujic, Martina Sanlorenzo, Susana Ortiz-Urda
{"title":"New insights in melanoma biomarkers: long-noncoding RNAs.","authors":"Ricardo Moreno-Traspas,&nbsp;Igor Vujic,&nbsp;Martina Sanlorenzo,&nbsp;Susana Ortiz-Urda","doi":"10.2217/mmt-2016-0008","DOIUrl":"https://doi.org/10.2217/mmt-2016-0008","url":null,"abstract":"<p><p>Melanoma is one of the leading cancers worldwide, distinguished for its malignancy and low survival rates. Although the poor outcome could improve with an early diagnosis and a good monitoring of the disease, current melanoma biomarkers display several limitations which make them useless. Interestingly, long-noncoding RNAs are secreted into the bloodstream inside exosomes by a wide range of malignant cells, and several of them have been validated as promising circulating molecular signatures of other tumors, but not melanoma. In this review we propose to explore the booming field of long-noncoding RNAs in order to find potential candidates to be tested as novel melanoma biomarkers, with the ultimate goal of improving melanoma detection, diagnosis and prognosis.</p>","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":"3 3","pages":"195-205"},"PeriodicalIF":3.6,"publicationDate":"2016-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/mmt-2016-0008","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36469760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pin1-FOXM1 inhibitors: a potential therapeutic for metastatic melanoma? Pin1-FOXM1抑制剂:转移性黑色素瘤的潜在治疗方法?
IF 3.6
Melanoma Management Pub Date : 2016-09-01 Epub Date: 2016-08-31 DOI: 10.2217/mmt-2016-0010
Peter Lj de Keizer
{"title":"Pin1-FOXM1 inhibitors: a potential therapeutic for metastatic melanoma?","authors":"Peter Lj de Keizer","doi":"10.2217/mmt-2016-0010","DOIUrl":"https://doi.org/10.2217/mmt-2016-0010","url":null,"abstract":"*Erasmus University Medical Center, Department of Genetics, Wytemaweg 80, 3015CN Rotterdam, The Netherlands; p.dekeizer@erasmusmc.nl","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":"3 3","pages":"161-164"},"PeriodicalIF":3.6,"publicationDate":"2016-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/mmt-2016-0010","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36465611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
PD-L1 in melanoma: facts and myths. PD-L1在黑色素瘤中的作用:事实和误解。
IF 3.6
Melanoma Management Pub Date : 2016-09-01 Epub Date: 2016-08-22 DOI: 10.2217/mmt-2016-0013
Mario Mandalà, Barbara Merelli, Daniela Massi
{"title":"PD-L1 in melanoma: facts and myths.","authors":"Mario Mandalà,&nbsp;Barbara Merelli,&nbsp;Daniela Massi","doi":"10.2217/mmt-2016-0013","DOIUrl":"https://doi.org/10.2217/mmt-2016-0013","url":null,"abstract":"<p><p>The use of monoclonal antibodies that block immunologic checkpoints that would otherwise mediate the adaptive immune resistance have paved the way in cancer treatment. There is evidence that blocking the PD-1/PD-L1 axis is a strategy of overriding importance in the treatment of patients with metastatic melanoma and other solid malignancies, some of which (NSCLC, colorectal cancer, renal cell cancer, head and neck cancer) were not considered to be 'immune-responsive' diseases until recently. In this perspective article, the biological and clinical relevance of PD-L1 is summarized in the context of the immune checkpoint inhibitors as a therapeutic strategy in metastatic melanoma patients.</p>","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":"3 3","pages":"187-194"},"PeriodicalIF":3.6,"publicationDate":"2016-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/mmt-2016-0013","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36469759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
Combination or single-agent ipilimumab as immunotherapy of advanced melanoma: a critical review. 联合或单药ipilimumab作为晚期黑色素瘤的免疫治疗:一个重要的回顾。
IF 3.6
Melanoma Management Pub Date : 2016-09-01 Epub Date: 2016-08-22 DOI: 10.2217/mmt-2016-0011
Omar Abdel-Rahman
{"title":"Combination or single-agent ipilimumab as immunotherapy of advanced melanoma: a critical review.","authors":"Omar Abdel-Rahman","doi":"10.2217/mmt-2016-0011","DOIUrl":"https://doi.org/10.2217/mmt-2016-0011","url":null,"abstract":"<p><strong>Aim: </strong>A pooled analysis of the efficacy and toxicity of combination immunotherapy versus single-agent ipilimumab in the management of advanced melanoma has been conducted.</p><p><strong>Methodology: </strong>Eligible studies included randomized controlled studies evaluating ipilimumab-based doublet immunotherapy versus ipilimumab monotherapy for the management of unresectable melanoma.</p><p><strong>Results: </strong>Nivolumab/ipilimumab combination strategy is associated with a significant improvement in objective response rate (odds ratio: 7.38; 95% CI: 3.71-14.67; p < 0.00001) and progression-free survival (0.42; 95% CI: 0.34-0.52; p < 0.00001) as well as a higher relative risk for high-grade elevated alanine aminotransferase (5.58; 95% CI: 2.28-13.67; p = 0.0002).</p><p><strong>Conclusion: </strong>This analysis demonstrated that nivolumab/ipilimumab combination is associated with a higher objective response rate and progression-free survival in the management of advanced melanoma.</p>","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":"3 3","pages":"231-243"},"PeriodicalIF":3.6,"publicationDate":"2016-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/mmt-2016-0011","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36469763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Advancements in unresectable melanoma: a multidisciplinary perspective. 不可切除黑色素瘤的进展:多学科视角。
IF 3.6
Melanoma Management Pub Date : 2016-09-01 Epub Date: 2016-08-16 DOI: 10.2217/mmt-2016-0003
Mary-Kate Malecek, June K Robinson, Karl Bilimoria, Jennifer N Choi, Jaehyuk Choi, Pedram Gerami, Timothy Kruser, Timothy Kuzel, Mary Martini, Jonathan B Strauss, Jeffrey Wayne, Jeffrey Sosman, Sunandana Chandra
{"title":"Advancements in unresectable melanoma: a multidisciplinary perspective.","authors":"Mary-Kate Malecek,&nbsp;June K Robinson,&nbsp;Karl Bilimoria,&nbsp;Jennifer N Choi,&nbsp;Jaehyuk Choi,&nbsp;Pedram Gerami,&nbsp;Timothy Kruser,&nbsp;Timothy Kuzel,&nbsp;Mary Martini,&nbsp;Jonathan B Strauss,&nbsp;Jeffrey Wayne,&nbsp;Jeffrey Sosman,&nbsp;Sunandana Chandra","doi":"10.2217/mmt-2016-0003","DOIUrl":"https://doi.org/10.2217/mmt-2016-0003","url":null,"abstract":"chemotherapy with alkylating agents as dacarbazine temozolomide. to reported in clinical trials Other alkylating agents and combination regimens of cytotoxic chemotherapy or biotherapy with inter-feron failed to show significant improvement in overall survival.","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":"3 3","pages":"171-175"},"PeriodicalIF":3.6,"publicationDate":"2016-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/mmt-2016-0003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36469757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The cutting edge of metastatic melanoma therapy. 转移性黑色素瘤治疗的前沿。
IF 3.6
Melanoma Management Pub Date : 2016-09-01 Epub Date: 2016-08-22 DOI: 10.2217/mmt-2016-0026
Antonia Digklia, Olivier Michielin
{"title":"The cutting edge of metastatic melanoma therapy.","authors":"Antonia Digklia,&nbsp;Olivier Michielin","doi":"10.2217/mmt-2016-0026","DOIUrl":"https://doi.org/10.2217/mmt-2016-0026","url":null,"abstract":"<p><p>The past decade has witnessed impressive new developments for the treatment of melanoma. The discovery of key oncogenic driver mutations, upon which tumor establishment and progression are dependent, changed the prognosis of patients with stage IV disease. Extensive preclinical and clinical studies have shown high response rates and survival benefits over conventional chemotherapies provided by target-specific inhibitors of BRAF- or NRAS-activating mutations. Recent genomic analyses of melanoma have also given new potentially targetable driver mutations. In addition, the quickened pace of development of immune checkpoint inhibitors for the treatment of melanoma offers the unique opportunity to provide a long-term clinical benefit. In this emerging era, predictive biomarkers for the selection of patients are required to help us develop an optimal therapeutic strategy.</p>","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":"3 3","pages":"217-229"},"PeriodicalIF":3.6,"publicationDate":"2016-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/mmt-2016-0026","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36469762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Outcomes and toxicity of stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab. 立体定向放射治疗接受伊匹单抗的黑色素瘤脑转移患者的预后和毒性。
IF 3.6
Melanoma Management Pub Date : 2016-09-01 Epub Date: 2016-08-22 DOI: 10.2217/mmt-2016-0004
Adam C Olson, Samantha Thomas, Rosie Qin, Bhavana Singh, Joseph K Salama, John Kirkpatrick, April Ks Salama
{"title":"Outcomes and toxicity of stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab.","authors":"Adam C Olson,&nbsp;Samantha Thomas,&nbsp;Rosie Qin,&nbsp;Bhavana Singh,&nbsp;Joseph K Salama,&nbsp;John Kirkpatrick,&nbsp;April Ks Salama","doi":"10.2217/mmt-2016-0004","DOIUrl":"https://doi.org/10.2217/mmt-2016-0004","url":null,"abstract":"<p><strong>Purpose: </strong>Patients with melanoma treated with ipilimumab and radiosurgery (stereotactic radiosurgery [SRS]) were reviewed for efficacy/safety.</p><p><strong>Methods: </strong>Patients who received ipilimumab and SRS for brain metastases were analyzed for control of SRS-treated metastasis and overall survival.</p><p><strong>Results: </strong>We identified 27 patients, 26 were assessable for outcomes. Median time-to-treated metastasis progression was 6.3 months (95% CI: 3.1-12.2). Overall survival was 23.4 months (95% CI: 5.7-not estimable) for SRS prior to/during ipilimumab (n = 14), and 10.4 months (95% CI: 1.9-not estimable) for SRS after ipilimumab (n = 12). Overall, no unexpected toxicities were seen: 11% of patients experienced grade 3 CNS toxicity and 7% developed radionecrosis.</p><p><strong>Conclusion: </strong>SRS for melanoma brain metastases with ipilimumab was well-tolerated. There may be improved survival for patients receiving SRS prior to/during ipilimumab.</p>","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":"3 3","pages":"177-186"},"PeriodicalIF":3.6,"publicationDate":"2016-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/mmt-2016-0004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36469758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 10
40 years in melanoma research: an interview with Meenhard Herlyn about his career in research and the outlook for the field. 黑素瘤研究40年:采访Meenhard Herlyn关于他的研究生涯和该领域的前景。
IF 3.6
Melanoma Management Pub Date : 2016-09-01 Epub Date: 2016-08-16 DOI: 10.2217/mmt-2016-0015
Meenhard Herlyn
{"title":"40 years in melanoma research: an interview with Meenhard Herlyn about his career in research and the outlook for the field.","authors":"Meenhard Herlyn","doi":"10.2217/mmt-2016-0015","DOIUrl":"https://doi.org/10.2217/mmt-2016-0015","url":null,"abstract":"<p><p><b>Meenhard Herlyn speaks to Sebastian Dennis-Beron, Commissioning Editor:</b> Dr Meenhard Herlyn is Caspar Wistar Professor for Melanoma Research and Director of the Melanoma Research Center at The Wistar Institute in Philadelphia, as well as Founding President of the Society for Melanoma Research. He has been a cancer researcher since arriving at Wistar in 1976 and has worked in melanoma research since 1977. Current major efforts include the ability to model the microenvironment of normal and diseased human tissue through 3D artificial skin, providing his laboratory with a unique insight into cancer research. His laboratory also seeks to further define the various signaling pathways that work in cancer cells in order to discover new opportunities to inhibit cancer growth through targeted therapeutics. Since therapy is increasingly guided by the genetic aberrations in tumors, Dr Herlyn and colleagues are developing combinations of compounds that take into account the genetic signature of tumors, with the specific goal of individualized cancer therapy. Another major effort of his laboratory is the study of therapy resistance and tumor dormancy. Tumor cells can become dormant in primary tumors or at any time after metastatic dissemination and can persist in the dormant state for many years, allowing tumors to resist treatment. Dr Herlyn's working hypothesis is that defined tumor subpopulations are central to dormancy and drug resistance due to their slow turnover and their nonresponsiveness to growth signals. His efforts seek to define how tumor cells escape dormancy for growth, invasion and metastasis, and how to best develop strategies for therapy. Because of the significance of immunotherapy in treatment of melanoma patients, the laboratory has developed two models that closely mimic the conditions in humans with the ultimate goal of combining targeted and immune therapies.</p>","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":"3 3","pages":"165-169"},"PeriodicalIF":3.6,"publicationDate":"2016-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/mmt-2016-0015","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36469756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Copper suppression as cancer therapy: the rationale for copper chelating agents in BRAFV600 mutated melanoma. 铜抑制作为癌症治疗:铜螯合剂治疗BRAFV600突变黑色素瘤的基本原理
IF 3.6
Melanoma Management Pub Date : 2016-09-01 Epub Date: 2016-09-02 DOI: 10.2217/mmt-2015-0005
Sarah Sammons, Donita Brady, Linda Vahdat, April Ks Salama
{"title":"Copper suppression as cancer therapy: the rationale for copper chelating agents in <i>BRAF</i><sup>V600</sup> mutated melanoma.","authors":"Sarah Sammons,&nbsp;Donita Brady,&nbsp;Linda Vahdat,&nbsp;April Ks Salama","doi":"10.2217/mmt-2015-0005","DOIUrl":"https://doi.org/10.2217/mmt-2015-0005","url":null,"abstract":"<p><p>The successful targeting of oncogenic <i>BRAF</i><sup>V600</sup> represents one of the landmark breakthroughs in therapy for advanced melanoma. While the initial clinical benefit can be dramatic, resistance is common due to a number of mechanisms, including MAPK pathway reactivation. Recent data have revealed a novel role for copper (Cu) in BRAF signaling with potential clinical implications. The history, preclinical data and efficacy of Cu chelating agents in cancer, specifically tetrathiomolybdate, will be reviewed with a focus on the rationale for targeting the MAPK cascade in melanoma through novel combination strategies.</p>","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":"3 3","pages":"207-216"},"PeriodicalIF":3.6,"publicationDate":"2016-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/mmt-2015-0005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36469761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 16
首页 上一页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信